SCHEMBL5886795

SCHEMBL5886795

CSc1nc(C)c2ccc(=O)n(-c3ccc(C(=O)NCc4ccccc4)cc3)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
TP53 P04637 1/20 0.46
LMNA P02545 3/20 0.44
ALDH1A1 P00352 3/20 0.44
PPARG P37231 1/20 0.42
RXFP1 Q9HBX9 2/20 0.42
POLB P06746 3/20 0.42
HDAC1 Q13547 1/20 0.42
MAPK8 P45983 2/20 0.42
MAPK9 P45984 2/20 0.42
MAPK10 P53779 2/20 0.42
RAB9A P51151 1/20 0.41
KDR P35968 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
THRB P10828 1/20 0.41
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41
AKT3 Q9Y243 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887115 0.87 TP53 (0.42) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL5886955 0.86 MAPT (0.48) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL5886976 0.85 POLB (0.47) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL5886724 0.84 MAPT (0.41) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL5887116 0.84 MAPT (0.46) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL5887441 0.84 TP53 (0.42) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL5886944 0.82 RXRA (0.47) MAPTALDH1A1POLBMEN1KMT2A
SCHEMBL5886779 0.82 MAPT (0.44) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL5886840 0.82 MAPT (0.44) MAPTTP53LMNAALDH1A1RXFP1
SCHEMBL5886891 0.81 TP53 (0.44) MAPTTP53LMNAALDH1A1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US disclosed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP MAPT 1614/4885TP53 43/4885LMNA 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.